RKTO
Rocket One Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Rocket One Inc.
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Rocket One Inc.
0.45
pre 0.46 −0.48%
0.00%
RKTO weight · VTI
No changes.
No changes.
No trades yet today.
No trades yet today.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Rocket One Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Rocket One Inc..
Annual filing, covered
10-K parsed · Mar 27 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 27 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Expected move
No implied move.
Bull1
Bear2
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $683,291 | 42.25% | +426.86% |
| Jane Street | $219,316 | 13.56% | new |
| UBS | $211,304 | 13.06% | +33.76% |
| Geodeindex-like | $195,982 | 12.12% | −8.52% |
| Vanguard Fiduciary Trustindex-like | $84,318 | 5.21% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $683,291 | 42.25% | +426.86% |
| Jane Street | $219,316 | 13.56% | new |
| UBS | $211,304 | 13.06% | +33.76% |
| Geodeindex-like | $195,982 | 12.12% | −8.52% |
| Vanguard Fiduciary Trustindex-like | $84,318 | 5.21% | 0.00% |
+76.66%
shares held · 10 largest managers